 SEATTLE, Feb. 28, 2022 GLOBE NEWSWIRE -- Impel NeuroPharma NASDAQ: IMPL, a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences. 